MaxCyte
enabled active clinical trials | MaxCyte
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
13 of 21
Related slides by other companies
MindMed
Investor Presentation
April 2021
develop phase a clinical trial | MindMed
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Arbutus Biopharma
Investor Presentation
August 2023
next generation oral | Arbutus Biopharma
Imara
Mergers and Acquisitions
October 2022
clinical development strategy i | Imara
Other recent decks by MaxCyte
See all presentations (8 decks)
Results
November 2023
Investor Presentation
October 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights